The University of California and UCLA Department of Pathology have signed an agreement with Centre Testing International Corp., to create a company that will operate a clinical laboratory in Shanghai. The new lab will support clinical trials and enhance medical care for Chinese patients with cancer and other diseases. The new company, CTI-Pathology/UCLA Health, is jointly owned by CTI and the University of California.

The 25,000-square-foot facility in China will offer genetic and molecular diagnostics and other sophisticated tests that exceed the scope of the average lab in China, and UCLA pathologists will train Chinese lab specialists to accurately interpret the tests. The lab is expected to open in September.